ebselen has been researched along with Disease Models, Animal in 62 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study investigated the effects of ebselen on the activity of acethylcholinesterase (AChE) isoforms in vitro and in an amnesia model induced by scopolamine in Swiss mice." | 7.88 | Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates scopolamine-induced amnesia in mice. ( Brüning, CA; Martini, F; Nogueira, CW; Pesarico, AP; Zeni, G, 2018) |
| "The aim of this study was to evaluate the effects of diphenyl diselenide (PhSe)2 and ebselen (EB) in ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in rats." | 7.83 | Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen. ( Danielski, LG; Florentino, D; Giustina, AD; Goldim, MP; Leffa, DD; Mendonça, MG; Michels, M; Pereira, GW; Pereira, VD; Petronilho, F; Piacentini, B; Rocha, JB; Tournier, M; Vieira, A, 2016) |
| " We hypothesized that ebselen via its ability to reduce reactive oxygen species (ROS) and augment nuclear factor-like 2 (Nrf2) anti-oxidants would attenuate hypoxia-induced damage to macroglial Müller cells and also lessen retinal vasculopathy." | 7.81 | Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Müller cell and vascular injury in the retina. ( de Haan, JB; Deliyanti, D; Figgett, WA; Talia, DM; Tan, SM; Wilkinson-Berka, JL, 2015) |
| "Ebselen had a protective effect on cataract development in a sodium-selenite-induced experimental model." | 7.78 | Protective effects of ebselen on sodium-selenite-induced experimental cataract in rats. ( Aydemir, O; Deniz, N; Güler, M; Kaya, MK; Üstündağ, B, 2012) |
| "This study indicates that ebselen may be neuroprotective when administered shortly after an embolic stroke, but the time- and dose-response analyses suggest that it has a narrow therapeutic window." | 7.72 | Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2003) |
| "We investigated the infarct-limiting effect of a selenoorganic compound, ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], in a canine coronary artery occlusion-reperfusion model of myocardial infarction." | 7.69 | Ebselen protects against ischemia-reperfusion injury in a canine model of myocardial infarction. ( Hori, M; Hoshida, S; Kamada, T; Kuzuya, T; Nishida, M; Tada, M; Yamashita, N, 1994) |
| "This study evaluated the effects of the seleno-organic substance Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one] in two models of acute hemorrhagic and acute edematous pancreatitis." | 7.68 | Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Lüthen, R; Niederau, C; Niederau, M; Strohmeyer, G; Ude, K, 1991) |
| "Ebselen was subsequently evaluated in MRSA-infected PUs in two models using obese and diabetic mice." | 5.62 | Evaluation of ebselen in resolving a methicillin-resistant Staphylococcus aureus infection of pressure ulcers in obese and diabetic mice. ( Abutaleb, NS; Dieterly, AM; Lyle, LT; Mohammad, H; Seleem, MN, 2021) |
| "Ebselen, is an organoselenium compound, already successfully approved in clinical trials as a repositioned drug for the treatment of bipolar disorder and prevention of noise-induced hearing loss." | 5.62 | Efficacy of Ebselen Against Invasive Aspergillosis in a Murine Model. ( Arita, GS; Becker, TCA; Bonfim-Mendonça, PS; Capoci, IRG; Conrado, PCV; Faria, DR; Kioshima, ES; Rodrigues-Vendramini, FAV; Sakita, KM; Svidzinski, TIE, 2021) |
| "Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue." | 5.40 | Effects of ebselen on ischemia/reperfusion injury in rat brain. ( Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014) |
| "Ebselen was administered to animals in the treatment group 2 hours prior to the induction of forebrain ischemia, and placebo was administered in the control group." | 5.37 | Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. ( Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011) |
| "Ebselen was the only treatment able to decrease MDA concentration to control values, exerting an effect similar to that elicited by L-NAME on the rest of the parameters tested." | 5.31 | Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen. ( Bosch-Morell, F; Díaz-Llopis, M; Johnsen-Soriano, S; Marín, N; Rodriguez-Galietero, A; Romá, J; Romero, B; Romero, FJ, 2002) |
| "Ebselen pretreatment inhibited neutrophil influx and activation as assessed by BAL fluid cellularity and myeloperoxidase activity in cell-free BAL and BAL cell homogenates." | 5.31 | Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. ( Belvisi, MG; Birrell, MA; Chen, B; Dabrowski, D; De Sanctis, GT; Foster, ML; Haddad, el-B; McCluskie, K; Pecoraro, M; Underwood, S; Webber, SE, 2002) |
| "Lithium, commonly used to treat bipolar disorder, potentiates the ability of the muscarinic agonist pilocarpine to induce seizures in rodents." | 3.96 | Effects of the putative lithium mimetic ebselen on pilocarpine-induced neural activity. ( Agam, G; Batra, AS; Belmaker, RH; Blackburn, V; Churchill, GC; Sade, Y; Saiardi, A; Serres, F; Sharp, T; Singh, N; Toker, L; Vasudevan, SR, 2020) |
| " This study investigated the effects of ebselen on the activity of acethylcholinesterase (AChE) isoforms in vitro and in an amnesia model induced by scopolamine in Swiss mice." | 3.88 | Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates scopolamine-induced amnesia in mice. ( Brüning, CA; Martini, F; Nogueira, CW; Pesarico, AP; Zeni, G, 2018) |
| "The aim of this study was to evaluate the effects of diphenyl diselenide (PhSe)2 and ebselen (EB) in ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in rats." | 3.83 | Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen. ( Danielski, LG; Florentino, D; Giustina, AD; Goldim, MP; Leffa, DD; Mendonça, MG; Michels, M; Pereira, GW; Pereira, VD; Petronilho, F; Piacentini, B; Rocha, JB; Tournier, M; Vieira, A, 2016) |
| " We hypothesized that ebselen via its ability to reduce reactive oxygen species (ROS) and augment nuclear factor-like 2 (Nrf2) anti-oxidants would attenuate hypoxia-induced damage to macroglial Müller cells and also lessen retinal vasculopathy." | 3.81 | Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Müller cell and vascular injury in the retina. ( de Haan, JB; Deliyanti, D; Figgett, WA; Talia, DM; Tan, SM; Wilkinson-Berka, JL, 2015) |
| "Ebselen had a protective effect on cataract development in a sodium-selenite-induced experimental model." | 3.78 | Protective effects of ebselen on sodium-selenite-induced experimental cataract in rats. ( Aydemir, O; Deniz, N; Güler, M; Kaya, MK; Üstündağ, B, 2012) |
| "This study indicates that ebselen may be neuroprotective when administered shortly after an embolic stroke, but the time- and dose-response analyses suggest that it has a narrow therapeutic window." | 3.72 | Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2003) |
| "Although ebselen, a seleno-organic compound, inhibits inflammation in various animal models, its efficacy as an anti-asthma drug remains to be clarified." | 3.71 | Ebselen suppresses late airway responses and airway inflammation in guinea pigs. ( Hirano, K; Iijima, H; Iishii, Y; Masuyama, K; Mochizuki, M; Morishima, Y; Nomura, A; Sakamoto, T; Sekizawa, K; Uchida, Y; Zhang, M, 2002) |
| "We investigated the infarct-limiting effect of a selenoorganic compound, ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one], in a canine coronary artery occlusion-reperfusion model of myocardial infarction." | 3.69 | Ebselen protects against ischemia-reperfusion injury in a canine model of myocardial infarction. ( Hori, M; Hoshida, S; Kamada, T; Kuzuya, T; Nishida, M; Tada, M; Yamashita, N, 1994) |
| "This study evaluated the effects of the seleno-organic substance Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one] in two models of acute hemorrhagic and acute edematous pancreatitis." | 3.68 | Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Lüthen, R; Niederau, C; Niederau, M; Strohmeyer, G; Ude, K, 1991) |
| "Ebselen has tremendous pharmacological importance for some diseases due to its antioxidant, antiapoptotic, and anti-inflammatory features." | 1.91 | Ebselen, an Active Seleno-Organic Compound, Alleviates Articular Cartilage Degeneration in a Rat Model of Knee Osteoarthritis. ( Kaçmaz, F; Kalacı, A; Karaboğa, İ; Okuyan, HM; Yurtal, Z, 2023) |
| "Ebselen was subsequently evaluated in MRSA-infected PUs in two models using obese and diabetic mice." | 1.62 | Evaluation of ebselen in resolving a methicillin-resistant Staphylococcus aureus infection of pressure ulcers in obese and diabetic mice. ( Abutaleb, NS; Dieterly, AM; Lyle, LT; Mohammad, H; Seleem, MN, 2021) |
| "Ebselen, is an organoselenium compound, already successfully approved in clinical trials as a repositioned drug for the treatment of bipolar disorder and prevention of noise-induced hearing loss." | 1.62 | Efficacy of Ebselen Against Invasive Aspergillosis in a Murine Model. ( Arita, GS; Becker, TCA; Bonfim-Mendonça, PS; Capoci, IRG; Conrado, PCV; Faria, DR; Kioshima, ES; Rodrigues-Vendramini, FAV; Sakita, KM; Svidzinski, TIE, 2021) |
| "Ebselen reversed the increase in the hepatic GST activity of the STZ-injected mice." | 1.56 | Ebselen reversed peripheral oxidative stress induced by a mouse model of sporadic Alzheimer's disease. ( Klann, IP; Martini, F; Nogueira, CW; Rosa, SG, 2020) |
| "Treatment with ebselen and silver ion significantly reduced bacterial loads, down-regulated the expression levels of tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) on-site and decreased white/red blood cell counts in mild cystitis model mice, which demonstrated the anti-inflammatory property of these agents." | 1.56 | Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion. ( Dong, C; Lu, Q; Wang, J; Wang, P; Xie, Z; Zhao, Y; Zhou, J; Zou, L, 2020) |
| "Oxidative stress is increased in COPD, IAV-induced lung inflammation and AECOPD." | 1.43 | Apocynin and ebselen reduce influenza A virus-induced lung inflammation in cigarette smoke-exposed mice. ( Bozinovski, S; Gunasinghe, P; Oostwoud, LC; Selemidis, S; Seow, HJ; Vlahos, R; Ye, JM, 2016) |
| "Ebselen treatment significantly ameliorated the neurological injury of TBI rats in a dose-dependent manner." | 1.40 | Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and p38 mitogen-activated protein kinase signalling pathway. ( Sun, Z; Wang, Q; Wei, L; Yang, C; Zhang, Y; Zhuang, Z, 2014) |
| "Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue." | 1.40 | Effects of ebselen on ischemia/reperfusion injury in rat brain. ( Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014) |
| "Ebselen was administered to animals in the treatment group 2 hours prior to the induction of forebrain ischemia, and placebo was administered in the control group." | 1.37 | Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. ( Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011) |
| "The late phase nasal blockage induced 4 h after the challenge was largely suppressed by ebselen (57% inhibition; P<0." | 1.35 | Involvement of peroxynitrite in pollen-induced nasal blockage in guinea pigs. ( Fujii, M; Kohno, S; Mizutani, N; Nabe, T; Yoshino, S, 2008) |
| "Chronic iron overload is a major cause of cardiac failure throughout the world, but its pathogenesis remains to be clarified." | 1.32 | Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice. ( Bartfay, WJ; Davis, MT, 2004) |
| "Treatment with Ebselen partially prevented the decrease in capillary density and angiogenic competence of renal explants, and restored acetylcholine-induced vasorelaxation in 22-week-old ZDF rats." | 1.32 | Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. ( Brodsky, SV; Chander, PN; Friedli, C; Gealekman, O; Goligorsky, MS; Nasjletti, A; Zhang, F, 2004) |
| "Ebselen was the only treatment able to decrease MDA concentration to control values, exerting an effect similar to that elicited by L-NAME on the rest of the parameters tested." | 1.31 | Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen. ( Bosch-Morell, F; Díaz-Llopis, M; Johnsen-Soriano, S; Marín, N; Rodriguez-Galietero, A; Romá, J; Romero, B; Romero, FJ, 2002) |
| "Ebselen is an antioxidant drug with glutathione peroxidase-like activity and a proven neuroprotective action in stroke patients." | 1.31 | The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. ( Blanchard, V; Daniel, N; Imperato, A; Moussaoui, S; Obinu, MC; Reibaud, M, 2000) |
| "Ebselen treatment diminished the cytochrome c release at 12 and 24 hours." | 1.31 | Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. ( Kikuchi, H; Masayasu, H; Nagata, I; Namura, S; Takami, S, 2001) |
| "Ebselen pretreatment inhibited neutrophil influx and activation as assessed by BAL fluid cellularity and myeloperoxidase activity in cell-free BAL and BAL cell homogenates." | 1.31 | Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. ( Belvisi, MG; Birrell, MA; Chen, B; Dabrowski, D; De Sanctis, GT; Foster, ML; Haddad, el-B; McCluskie, K; Pecoraro, M; Underwood, S; Webber, SE, 2002) |
| "3." | 1.30 | Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. ( Graham, DI; Macrae, IM; Masayasu, H; Peters, EE; Takasago, T, 1997) |
| "Pretreatment with ebselen (10 or 30 mg/kg p." | 1.29 | The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. ( Dawson, DA; Graham, DI; Macrae, IM; Masayasu, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (9.68) | 18.2507 |
| 2000's | 21 (33.87) | 29.6817 |
| 2010's | 23 (37.10) | 24.3611 |
| 2020's | 12 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Bijian, K | 1 |
| Zhang, Z | 1 |
| Xu, B | 1 |
| Jie, S | 1 |
| Chen, B | 2 |
| Wan, S | 1 |
| Wu, J | 1 |
| Jiang, T | 1 |
| Alaoui-Jamali, MA | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 2 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Okuyan, HM | 1 |
| Yurtal, Z | 1 |
| Karaboğa, İ | 1 |
| Kaçmaz, F | 1 |
| Kalacı, A | 1 |
| Huang, HP | 1 |
| Chiang, W | 1 |
| Stone, L | 1 |
| Kang, CK | 1 |
| Chuang, CY | 1 |
| Kuo, HC | 1 |
| Klann, IP | 2 |
| Martini, F | 3 |
| Rosa, SG | 2 |
| Nogueira, CW | 5 |
| Garland, M | 1 |
| Hryckowian, AJ | 1 |
| Tholen, M | 1 |
| Bender, KO | 1 |
| Van Treuren, WW | 1 |
| Loscher, S | 1 |
| Sonnenburg, JL | 1 |
| Bogyo, M | 1 |
| Singh, N | 1 |
| Serres, F | 1 |
| Toker, L | 1 |
| Sade, Y | 1 |
| Blackburn, V | 1 |
| Batra, AS | 1 |
| Saiardi, A | 1 |
| Agam, G | 1 |
| Belmaker, RH | 1 |
| Sharp, T | 1 |
| Vasudevan, SR | 1 |
| Churchill, GC | 1 |
| Amporndanai, K | 1 |
| Rogers, M | 1 |
| Watanabe, S | 1 |
| Yamanaka, K | 1 |
| O'Neill, PM | 1 |
| Hasnain, SS | 1 |
| Yerbury, JJ | 1 |
| Cashman, NR | 1 |
| Wang, P | 1 |
| Wang, J | 2 |
| Xie, Z | 1 |
| Zhou, J | 1 |
| Lu, Q | 1 |
| Zhao, Y | 1 |
| Dong, C | 1 |
| Zou, L | 2 |
| Mohammad, H | 1 |
| Abutaleb, NS | 1 |
| Dieterly, AM | 1 |
| Lyle, LT | 1 |
| Seleem, MN | 1 |
| Menon, S | 1 |
| Vartak, R | 1 |
| Patel, K | 1 |
| Billack, B | 1 |
| Youssef, MI | 1 |
| Ma, J | 1 |
| Chen, Z | 1 |
| Hu, WW | 1 |
| Sakita, KM | 1 |
| Capoci, IRG | 1 |
| Conrado, PCV | 1 |
| Rodrigues-Vendramini, FAV | 1 |
| Faria, DR | 1 |
| Arita, GS | 1 |
| Becker, TCA | 1 |
| Bonfim-Mendonça, PS | 1 |
| Svidzinski, TIE | 1 |
| Kioshima, ES | 1 |
| Lu, J | 1 |
| Ren, X | 1 |
| Zhang, L | 1 |
| Gao, Y | 1 |
| Rottenberg, ME | 1 |
| Holmgren, A | 1 |
| Pesarico, AP | 1 |
| Brüning, CA | 1 |
| Zeni, G | 2 |
| Fulco, BCW | 1 |
| Carvalho, FB | 1 |
| Rahmeier, FL | 1 |
| Fernandes, MC | 1 |
| Kagota, S | 1 |
| Maruyama, K | 1 |
| Tada, Y | 1 |
| Fukushima, K | 1 |
| Umetani, K | 1 |
| Wakuda, H | 1 |
| Shinozuka, K | 1 |
| Wei, L | 1 |
| Zhang, Y | 1 |
| Yang, C | 1 |
| Wang, Q | 1 |
| Zhuang, Z | 1 |
| Sun, Z | 1 |
| Aras, M | 1 |
| Altaş, M | 1 |
| Meydan, S | 1 |
| Nacar, E | 1 |
| Karcıoğlu, M | 1 |
| Ulutaş, KT | 1 |
| Serarslan, Y | 1 |
| Silvestre, F | 2 |
| Danielski, LG | 3 |
| Michels, M | 2 |
| Florentino, D | 3 |
| Vieira, A | 3 |
| Souza, L | 1 |
| Cardoso, LC | 1 |
| Schraiber, R | 1 |
| Rezin, GT | 1 |
| Vuolo, F | 1 |
| da Rocha, JB | 1 |
| Barichello, T | 2 |
| Quevedo, J | 2 |
| Dal-Pizzol, F | 1 |
| Petronilho, F | 3 |
| Tan, SM | 2 |
| Sharma, A | 1 |
| Stefanovic, N | 1 |
| de Haan, JB | 2 |
| Nascimento, DZ | 1 |
| Kanis, LA | 1 |
| Fortunato, JJ | 1 |
| Badawy, M | 1 |
| Deliyanti, D | 1 |
| Figgett, WA | 1 |
| Talia, DM | 1 |
| Wilkinson-Berka, JL | 1 |
| Oostwoud, LC | 1 |
| Gunasinghe, P | 1 |
| Seow, HJ | 1 |
| Ye, JM | 1 |
| Selemidis, S | 1 |
| Bozinovski, S | 2 |
| Vlahos, R | 1 |
| Goldim, MP | 1 |
| Mendonça, MG | 1 |
| Tournier, M | 1 |
| Piacentini, B | 1 |
| Giustina, AD | 1 |
| Leffa, DD | 1 |
| Pereira, GW | 1 |
| Pereira, VD | 1 |
| Rocha, JB | 4 |
| Wong, CH | 1 |
| Hertzog, PJ | 1 |
| Hickey, MJ | 1 |
| Crack, PJ | 1 |
| Mazzanti, CM | 1 |
| Spanevello, R | 1 |
| Ahmed, M | 1 |
| Pereira, LB | 1 |
| Gonçalves, JF | 1 |
| Corrêa, M | 1 |
| Schmatz, R | 1 |
| Stefanello, N | 1 |
| Leal, DB | 1 |
| Mazzanti, A | 1 |
| Ramos, AT | 1 |
| Martins, TB | 1 |
| Danesi, CC | 1 |
| Graça, DL | 1 |
| Morsch, VM | 1 |
| Schetinger, MR | 1 |
| Guven, A | 1 |
| Tunc, T | 1 |
| Topal, T | 1 |
| Kul, M | 1 |
| Korkmaz, A | 1 |
| Gundogdu, G | 1 |
| Onguru, O | 1 |
| Ozturk, H | 1 |
| Meotti, FC | 1 |
| Coelho, IS | 1 |
| Franco, JL | 1 |
| Dafre, AL | 1 |
| Santos, AR | 1 |
| Koizumi, H | 1 |
| Fujisawa, H | 1 |
| Suehiro, E | 1 |
| Shirao, S | 1 |
| Suzuki, M | 2 |
| Park, JG | 1 |
| Yoo, JY | 1 |
| Jeong, SJ | 1 |
| Choi, JH | 1 |
| Lee, MR | 1 |
| Lee, MN | 1 |
| Hwa Lee, J | 1 |
| Kim, HC | 1 |
| Jo, H | 1 |
| Yu, DY | 1 |
| Kang, SW | 1 |
| Rhee, SG | 1 |
| Oh, GT | 1 |
| Dalla Corte, CL | 1 |
| Bastos, LL | 1 |
| Dobrachinski, F | 1 |
| Soares, FA | 1 |
| Santos, AP | 1 |
| Lucas, RL | 1 |
| Andrade, V | 1 |
| Mateus, ML | 1 |
| Milatovic, D | 1 |
| Aschner, M | 1 |
| Batoreu, MC | 1 |
| Kumfu, S | 2 |
| Chattipakorn, S | 2 |
| Chinda, K | 1 |
| Fucharoen, S | 2 |
| Chattipakorn, N | 2 |
| Aydemir, O | 1 |
| Güler, M | 1 |
| Kaya, MK | 1 |
| Deniz, N | 1 |
| Üstündağ, B | 1 |
| Minnerup, J | 1 |
| Sutherland, BA | 1 |
| Buchan, AM | 1 |
| Kleinschnitz, C | 1 |
| Bosch-Morell, F | 1 |
| Romá, J | 1 |
| Marín, N | 1 |
| Romero, B | 1 |
| Rodriguez-Galietero, A | 1 |
| Johnsen-Soriano, S | 1 |
| Díaz-Llopis, M | 1 |
| Romero, FJ | 1 |
| Burger, ME | 1 |
| Alves, A | 1 |
| Callegari, L | 1 |
| Athayde, FR | 1 |
| Lapchak, PA | 1 |
| Zivin, JA | 1 |
| Jean Harry, G | 1 |
| Bruccoleri, A | 1 |
| Lefebvre d'Hellencourt, C | 1 |
| Yokozawa, T | 1 |
| Rhyu, DY | 1 |
| Cho, EJ | 1 |
| Davis, MT | 1 |
| Bartfay, WJ | 1 |
| Gealekman, O | 1 |
| Brodsky, SV | 1 |
| Zhang, F | 1 |
| Chander, PN | 1 |
| Friedli, C | 1 |
| Nasjletti, A | 1 |
| Goligorsky, MS | 1 |
| Yamasoba, T | 1 |
| Pourbakht, A | 1 |
| Sakamoto, T | 2 |
| Dhanasekaran, M | 1 |
| Uthayathas, S | 1 |
| Karuppagounder, SS | 1 |
| Parameshwaran, K | 1 |
| Suppiramaniam, V | 1 |
| Ebadi, M | 1 |
| Brown-Borg, HM | 1 |
| Ardais, AP | 1 |
| Santos, FW | 1 |
| Mizutani, N | 1 |
| Nabe, T | 1 |
| Fujii, M | 1 |
| Yoshino, S | 1 |
| Kohno, S | 1 |
| Dawson, DA | 1 |
| Masayasu, H | 4 |
| Graham, DI | 3 |
| Macrae, IM | 3 |
| Hoshida, S | 1 |
| Kuzuya, T | 1 |
| Nishida, M | 1 |
| Yamashita, N | 1 |
| Hori, M | 1 |
| Kamada, T | 1 |
| Tada, M | 1 |
| Gao, JX | 1 |
| Issekutz, AC | 1 |
| Tabuchi, Y | 1 |
| Kurebayashi, Y | 1 |
| Takasago, T | 1 |
| Peters, EE | 1 |
| Rybak, LP | 1 |
| Husain, K | 1 |
| Morris, C | 1 |
| Whitworth, C | 1 |
| Somani, S | 1 |
| Moussaoui, S | 1 |
| Obinu, MC | 1 |
| Daniel, N | 1 |
| Reibaud, M | 1 |
| Blanchard, V | 1 |
| Imperato, A | 1 |
| Namura, S | 1 |
| Nagata, I | 1 |
| Takami, S | 1 |
| Kikuchi, H | 1 |
| Imai, H | 1 |
| Dewar, D | 1 |
| Zhang, M | 1 |
| Nomura, A | 1 |
| Uchida, Y | 1 |
| Iijima, H | 1 |
| Iishii, Y | 1 |
| Morishima, Y | 1 |
| Mochizuki, M | 1 |
| Masuyama, K | 1 |
| Hirano, K | 1 |
| Sekizawa, K | 1 |
| Haddad, el-B | 1 |
| McCluskie, K | 1 |
| Birrell, MA | 1 |
| Dabrowski, D | 1 |
| Pecoraro, M | 1 |
| Underwood, S | 1 |
| De Sanctis, GT | 1 |
| Webber, SE | 1 |
| Foster, ML | 1 |
| Belvisi, MG | 1 |
| Niederau, C | 1 |
| Ude, K | 1 |
| Niederau, M | 1 |
| Lüthen, R | 1 |
| Strohmeyer, G | 1 |
| Ferrell, LD | 1 |
| Grendell, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease[NCT02603081] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus[NCT00762671] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects[NCT01452607] | Phase 1 | 32 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift[NCT01444846] | Phase 2 | 83 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| The Protective Effect of Ginkgo Biloba Extract on Cisplatin-Induced Ototoxicity in Humans Beings Evaluated by Distortion Product Otoacoustic Emissions[NCT01139281] | Phase 2 | 15 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ebselen and Disease Models, Animal
| Article | Year |
|---|---|
Potential therapeutic agents for ischemic white matter damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Models, Animal; Edaravone; H | 2021 |
Neuroprotection for stroke: current status and future perspectives.
Topics: Animals; Antioxidants; Azoles; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; | 2012 |
60 other studies available for ebselen and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Mode | 2012 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Ebselen, an Active Seleno-Organic Compound, Alleviates Articular Cartilage Degeneration in a Rat Model of Knee Osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Morphogenetic Protein 2; Cartilage, Articular | 2023 |
Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential.
Topics: alpha-Glucosidases; Animals; Azoles; Blood-Brain Barrier; Brain; Cell Culture Techniques; Cells, Cul | 2019 |
Ebselen reversed peripheral oxidative stress induced by a mouse model of sporadic Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Azoles; Biomarkers; Catalysis; Disease Models, Animal; Gas | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
Effects of the putative lithium mimetic ebselen on pilocarpine-induced neural activity.
Topics: Animals; Anticonvulsants; Azoles; Brain; Calcium Signaling; CHO Cells; Cricetulus; Disease Models, A | 2020 |
Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Azoles; Betacoronavirus; Binding Sites; Cell Line, Tumor; Cr | 2020 |
Selenium-based compounds: Emerging players in the ever-unfolding story of SOD1 in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Azoles; Body Weight; Disease Models, Animal; Humans; Isoindo | 2020 |
Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.
Topics: Animals; Anti-Bacterial Agents; Azoles; Cystitis; Disease Models, Animal; Drug Resistance, Multiple, | 2020 |
Evaluation of ebselen in resolving a methicillin-resistant Staphylococcus aureus infection of pressure ulcers in obese and diabetic mice.
Topics: Animals; Anti-Bacterial Agents; Azoles; Diabetes Mellitus, Experimental; Disease Models, Animal; Iso | 2021 |
Evaluation of the antifungal activity of an ebselen-loaded nanoemulsion in a mouse model of vulvovaginal candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Disease Models, Animal; Emu | 2021 |
Efficacy of Ebselen Against Invasive Aspergillosis in a Murine Model.
Topics: Animals; Antifungal Agents; Aspergillosis; Azoles; Disease Models, Animal; Invasive Fungal Infection | 2021 |
Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Azoles; Cell Survival; Cells, Cultured; Disease Models, Animal; Drug | 2017 |
Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates scopolamine-induced amnesia in mice.
Topics: Acetylcholinesterase; Amnesia; Animals; Azoles; Behavior, Animal; Disease Models, Animal; Gene Expre | 2018 |
A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Azoles; Disease Models, Animal; Isoindoles; Mal | 2019 |
Chronic oxidative-nitrosative stress impairs coronary vasodilation in metabolic syndrome model rats.
Topics: Animals; Azoles; Coronary Vessels; Cyclic N-Oxides; Disease Models, Animal; Down-Regulation; Free Ra | 2013 |
Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and p38 mitogen-activated protein kinase signalling pathway.
Topics: Animals; Azoles; Blotting, Western; Brain Injuries; Disease Models, Animal; Dose-Response Relationsh | 2014 |
Effects of ebselen on ischemia/reperfusion injury in rat brain.
Topics: Animals; Azoles; Brain; Brain Ischemia; Catalase; Disease Models, Animal; Glutathione Peroxidase; Is | 2014 |
Effects of organoselenium compounds on early and late brain biochemical alterations in sepsis-survivor rats.
Topics: Animals; Azoles; Benzene Derivatives; Brain; Creatine Kinase; Disease Models, Animal; Electron Trans | 2014 |
Late-intervention study with ebselen in an experimental model of type 1 diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Azoles; Deoxyguanosine; Diabetes Mellitus, Type | 2015 |
Ebselen Attenuates Lung Injury in Experimental Model of Carrageenan-Induced Pleurisy in Rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Carrageenan; Disease Models, Animal; Isoin | 2015 |
Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Müller cell and vascular injury in the retina.
Topics: Animals; Animals, Newborn; Antioxidants; Azoles; Biomarkers; Blotting, Western; Cells, Cultured; Dis | 2015 |
Apocynin and ebselen reduce influenza A virus-induced lung inflammation in cigarette smoke-exposed mice.
Topics: Acetophenones; Animals; Azoles; Disease Models, Animal; Humans; Influenza A virus; Isoindoles; Male; | 2016 |
Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen.
Topics: Animals; Azoles; Benzene Derivatives; Catalase; Colitis; Colon; Disease Models, Animal; Inflammation | 2016 |
Absence of glutathione peroxidase-1 exacerbates cerebral ischemia-reperfusion injury by reducing post-ischemic microvascular perfusion.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation; Disea | 2008 |
Pre-treatment with ebselen and vitamin E modulate acetylcholinesterase activity: interaction with demyelinating agents.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antioxidants; Azoles; Brain; Cholinergic Fibers; Demye | 2009 |
Alpha-lipoic acid and ebselen prevent ischemia/reperfusion injury in the rat intestine.
Topics: Animals; Antioxidants; Azoles; Disease Models, Animal; Intestinal Diseases; Intestine, Small; Isoind | 2008 |
Redox modulation at the peripheral site alters nociceptive transmission in vivo.
Topics: Alkylating Agents; Analgesics; Animals; Azoles; Behavior, Animal; Buthionine Sulfoximine; Disease Mo | 2009 |
Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide.
Topics: Animals; Azoles; Brain Ischemia; CA1 Region, Hippocampal; Cerebrovascular Circulation; Disease Model | 2011 |
Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Antioxidants; Aorta; Apolipoproteins E; Atherosclerosis; Azoles; Bone Marrow Cells; Bone Ma | 2011 |
The combination of organoselenium compounds and guanosine prevents glutamate-induced oxidative stress in different regions of rat brains.
Topics: Animals; Antioxidants; Azoles; Benzene Derivatives; Brain; Brain Diseases, Metabolic; Disease Models | 2012 |
Protective effects of ebselen (Ebs) and para-aminosalicylic acid (PAS) against manganese (Mn)-induced neurotoxicity.
Topics: Aminosalicylic Acid; Animals; Azoles; Behavior, Animal; Biomarkers; Brain; Disease Models, Animal; I | 2012 |
T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice.
Topics: Animals; Azoles; Base Sequence; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels, L-Type | 2012 |
Protective effects of ebselen on sodium-selenite-induced experimental cataract in rats.
Topics: Animals; Antioxidants; Azoles; Cataract; Disease Models, Animal; Glutathione; Isoindoles; Lens, Crys | 2012 |
Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels.
Topics: Animals; Azoles; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-T | 2013 |
Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Azoles; Chlorpromazine; Disease Models, Animal; Enz | 2002 |
Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Azoles; Corpus Striatum; Disease Models, Animal | 2003 |
Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Topics: Animals; Antioxidants; Azoles; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2003 |
Differential modulation of hippocampal chemical-induced injury response by ebselen, pentoxifylline, and TNFalpha-, IL-1alpha-, and IL-6-neutralizing antibodies.
Topics: Animals; Antibodies; Azoles; Brain Injuries; Cerebellum; Cytokines; Disease Models, Animal; Drug Com | 2003 |
(-)-Epicatechin 3-O-gallate ameliorates the damages related to peroxynitrite production by mechanisms distinct from those of other free radical inhibitors.
Topics: Animals; Azoles; Blood Urea Nitrogen; Catechin; Copper; Creatinine; Disease Models, Animal; Dose-Res | 2004 |
Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice.
Topics: Animals; Antioxidants; Azoles; Cardiomyopathies; Chronic Disease; Cyclooxygenase Inhibitors; Disease | 2004 |
Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen.
Topics: Acetylcholine; Animals; Antioxidants; Azoles; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dis | 2004 |
Ebselen prevents noise-induced excitotoxicity and temporary threshold shift.
Topics: Animals; Auditory Threshold; Azoles; Cochlear Nerve; Dendrites; Disease Models, Animal; Evoked Poten | 2005 |
Ebselen effects on MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Azoles; Brain; Cell Line, Tumor | 2006 |
Ebselen attenuates cadmium-induced testicular damage in mice.
Topics: Alanine Transaminase; Animals; Antioxidants; Ascorbic Acid; Aspartate Aminotransferases; Azoles; Bio | 2008 |
Involvement of peroxynitrite in pollen-induced nasal blockage in guinea pigs.
Topics: Administration, Intranasal; Allergens; Allopurinol; Analysis of Variance; Animals; Antioxidants; Azo | 2008 |
The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.
Topics: Animals; Antioxidants; Azoles; Blood Pressure; Brain Ischemia; Caudate Nucleus; Cerebral Cortex; Dis | 1995 |
Ebselen protects against ischemia-reperfusion injury in a canine model of myocardial infarction.
Topics: Animals; Azoles; Blood Pressure; Constriction; Coronary Circulation; Coronary Vessels; Disease Model | 1994 |
The effect of ebselen on polymorphonuclear leukocyte migration to joints in rats with adjuvant arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Experimental; Azoles; Cel | 1993 |
Antisecretory and antiulcer effects of ebselen, a seleno-organic compound, in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Azoles; Disease Models, Animal; | 1993 |
Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Azoles; Brain Ischemia; Disease Mode | 1997 |
Effect of protective agents against cisplatin ototoxicity.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antioxidants; Azoles; Benzoates; Cisplatin; | 2000 |
The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Azoles; Behavior, Animal; Blood Proteins; Callit | 2000 |
Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice.
Topics: Animals; Apoptosis; Azoles; Blotting, Western; Brain; Caspase 3; Caspases; Cell Survival; Cytochrome | 2001 |
Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia.
Topics: Animals; Antioxidants; Axons; Azoles; Brain; Brain Ischemia; Disease Models, Animal; DNA Damage; Inf | 2001 |
Ebselen suppresses late airway responses and airway inflammation in guinea pigs.
Topics: Airway Resistance; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Area Under Curve; Asthm | 2002 |
Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation.
Topics: Aerosols; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Bronchi; Bronchoalveolar Lavage | 2002 |
Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Azoles; Ceruletide; Choline Deficiency; Diet; Disease Models, Anim | 1991 |